Alto Neuroscience, Inc.

Compare

521 Followers

ANRO Stock Chart & Stats

$14.04

-$0.09(-1.99%)

At close: Jan 08 4:00 PM EST

$14.04

-$0.09(-1.99%)

Day’s Range― - ―

52-Week Range$1.60 - $14.85

Previous CloseN/A

Volume104.17K

Average Volume (3M)2.30M

Market Cap

$164.63M

Enterprise Value-$60.72M

Total Cash (Recent Filing)$147.59M

Total Debt (Recent Filing)$4.21M

Price to Earnings (P/E)―

Beta1.95

Next Earnings

Nov 18, 2025

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding27,076,630

10 Day Avg. Volume557,199

30 Day Avg. Volume2,303,174

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.37

Enterprise Value/Revenue-154.11

Enterprise Value/Gross Profit221.60

Enterprise Value/Ebitda0.95

Forecast

1Y Price Target

$23.50

Price Target Upside67.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Development AccelerationALTO-207 has secured financing and a regulatory path has been cleared, allowing the pivotal TRD program to accelerate by approximately one year.

Financing And InvestmentA $50 million private placement financing was announced to support the development of ALTO-207 for treatment-resistant depression.

Regulatory ApprovalThe FDA granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia, validating Alto's precision-psychiatry approach.

Bears Say

Alto Neuroscience, Inc. News

Alto Neuroscience price target raised to $50 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Alto Neuroscience (ANRO) to $50 from $10 and keeps a...

6d ago

ANRO

Alto Neuroscience price target raised to $16 from $10 at Baird

Baird raised the firm’s price target on Alto Neuroscience (ANRO) to $16 from $10 and keeps an Outperform...

9d ago

ANRO

Midday Fly By: AWS hit by outage, Kering sells beauty unit

The major averages were broadly higher near noon as markets opened with a cautiously optimistic tone amid strong...

10d ago

Alto Neuroscience price target raised to $16 from $10 at Baird

Baird raised the firm’s price target on Alto Neuroscience (ANRO) to $16 from $10 and keeps an Outperform...

10d ago

ANRO

Alto Neuroscience to sell 3.832M shares at $5.91 in private placement

Alto Neuroscience (ANRO) announced that it has entered into a securities purchase agreement with institutional and accredited investors...

10d ago

ANRO

Alto Neuroscience plans to accelerate development of ALTO-207

Alto Neuroscience (ANRO) announced that, following a successful outcome from a recent FDA meeting, it plans to accelerate...

10d ago

ANRO

Morning Movers: Apple shares slip following Jefferies downgrade

Stock futures are trading higher this morning, driven by strong optimism that the Federal Reserve will cut rates...

27d ago

GME

RUM

Alto Neuroscience granted fast track designation for ALTO-101

Alto Neuroscience (ANRO) announced that the FDA has granted fast track designation to ALTO-101 for the treatment of...

27d ago

ANRO

Buy Recommendation for Alto Neuroscience Driven by Promising ALTO-207 Acquisition and Strategic Financial Backing

William Blair analyst Myles Minter has reiterated their bullish stance on ANRO stock, giving a Buy rating on...

11h ago

ANRO

Alto Neuroscience’s ALTO-101 Study: A Potential Game-Changer for Schizophrenia Treatment?

Alto Neuroscience, Inc. (($ANRO)) announced an update on their ongoing clinical study. Study Overview: Alto Neuroscience, Inc. is...

3d ago

ANRO

Alto Neuroscience’s ALTO-300 Study: A Potential Game-Changer in Depression Treatment

Alto Neuroscience, Inc. (($ANRO)) announced an update on their ongoing clinical study. Alto Neuroscience, Inc. is conducting a...

3d ago

ANRO

Alto Neuroscience’s ALTO-100 Study: A Potential Game-Changer for Bipolar Disorder Treatment?

Alto Neuroscience, Inc. (($ANRO)) announced an update on their ongoing clinical study. Alto Neuroscience, Inc. is conducting a...

3d ago

ANRO

Alto Neuroscience’s Strategic Advancements and Regulatory Milestones Justify Buy Rating

Alto Neuroscience, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio...

6d ago

ANRO

Alto Neuroscience Secures $50M in Private Placement

Alto Neuroscience, Inc. ( ($ANRO) ) just unveiled an announcement. On October 19, 2025, Alto Neuroscience, Inc. announced...

10d ago

ANRO

ANRO FAQ

What was Alto Neuroscience, Inc.’s price range in the past 12 months?

Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $14.85 in the past 12 months.

What is Alto Neuroscience, Inc.’s market cap?

Alto Neuroscience, Inc.’s market cap is $164.63M.

When is Alto Neuroscience, Inc.’s upcoming earnings report date?

Alto Neuroscience, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 19 days.

How were Alto Neuroscience, Inc.’s earnings last quarter?

Alto Neuroscience, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.599 by -$0.051.

Is Alto Neuroscience, Inc. overvalued?

According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alto Neuroscience, Inc. pay dividends?

Alto Neuroscience, Inc. does not currently pay dividends.

What is Alto Neuroscience, Inc.’s EPS estimate?

Alto Neuroscience, Inc.’s EPS estimate is -0.69.

How many shares outstanding does Alto Neuroscience, Inc. have?

Alto Neuroscience, Inc. has 27,076,630 shares outstanding.

What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?

Alto Neuroscience, Inc. reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.599. Following the earnings report the stock price went down -0.319%.

Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?

Currently, no hedge funds are holding shares in ANRO

Alto Neuroscience, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-42.78%

Trailing 12-Months

Asset Growth

-20.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (ANRO) is a biotechnology company focused on developing precision medicine approaches for the treatment of mental health disorders. The company leverages advancements in brain biomarkers and artificial intelligence to create personalized treatment plans for conditions such as depression and anxiety. By integrating cutting-edge neuroscience with clinical data, Alto aims to provide effective and targeted therapeutic solutions.

Alto Neuroscience, Inc. (ANRO) Earnings & Revenues

Historic Earnings Reports

ANRO Stock 12 Month Forecast

Average Price Target

$23.50

▲(67.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,7.603076923076923,11.136153846153846,14.66923076923077,18.20230769230769,21.735384615384618,25.26846153846154,28.801538461538463,32.33461538461539,35.86769230769231,39.400769230769235,42.933846153846154,46.46692307692308,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,5.564615384615385,7.059230769230769,8.553846153846155,10.048461538461538,11.543076923076924,13.037692307692309,14.532307692307693,16.026923076923076,17.521538461538462,19.01615384615385,20.51076923076923,22.005384615384617,{"y":23.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.07,4.756923076923077,5.443846153846154,6.13076923076923,6.817692307692308,7.504615384615384,8.19153846153846,8.878461538461538,9.565384615384616,10.252307692307692,10.939230769230768,11.626153846153846,12.313076923076922,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.81,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >